Pierre News Headlines

Lewy Body Dementia Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Eisai, EIP Pharma, Sun Pharma, H. Lundbeck A/S, GE Healthcare, Eli Lilly

 Breaking News
  • No posts were found

Lewy Body Dementia Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Eisai, EIP Pharma, Sun Pharma, H. Lundbeck A/S, GE Healthcare, Eli Lilly

May 30
10:32 2023
Lewy Body Dementia Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Eisai, EIP Pharma, Sun Pharma, H. Lundbeck A/S, GE Healthcare, Eli Lilly
DelveInsight’s “Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Lewy Body Dementia.

DelveInsight’s “Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Lewy Body Dementia, historical and forecasted epidemiology as well as the Lewy Body Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Lewy Body Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lewy Body Dementia Market Forecast

 

Some of the key facts of the Lewy Body Dementia Market Report: 

  • The Lewy Body Dementia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The condition typically lasts between 5 and 7 years from the time of diagnosis until death, but it can last anywhere between 2 and 20 years
  • Inskip et al.’s study, “Promoting independence in Lewy body dementia through exercise (PRIDE) study: Protocol for a pilot study,” published in 2019, noted that the prevalence of LBD varies and may account for up to 24% of all dementia diagnoses
  • Key Lewy Body Dementia Companies: Eisai, EIP Pharma, Sun Pharma, Neurological Research Center, Eli Lilly and Company, Axovant Sciences Ltd., Cognition Therapeutics, Athira Pharma, H. Lundbeck A/S, GE Healthcare, CuraSen Therapeutics, Cephalon, Sio Gene Therapies, Avid Radiopharmaceuticals, and others
  • Key Lewy Body Dementia Therapies: E2027, Neflamapimod, K0706, Galantamine, LY3154207, Nelotanserin, Neflamapimod, CT1812, Irsenontrine, Donepezi, ATH-1017, Memantine, DatSCAN, CST-103, Armodafinil, RVT-101, 18F-AV-133, and others
  • The Lewy Body Dementia epidemiology based on gender analyzed that it can be found that Lewy Body Dementia more commonly affects males than females
  • The Lewy Body Dementia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lewy Body Dementia pipeline products will significantly revolutionize the Lewy Body Dementia market dynamics.

 

Lewy Body Dementia Overview

The National Institute of Health (NIH) describes Lewy body dementia (LBD) as a condition characterised by aberrant accumulations of the protein alpha-synuclein in the brain. These deposits, also known as Lewy bodies, modify certain brain chemicals, and these modifications can result in issues with thought, movement, behaviour, and mood. One of the most prevalent types of dementia is Lewy body dementia.

 

Get a Free sample for the Lewy Body Dementia Market Report –

https://www.delveinsight.com/sample-request/lewy-body-dementia-market

 

Lewy Body Dementia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Lewy Body Dementia Epidemiology Segmentation:

The Lewy Body Dementia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Lewy Body Dementia
  • Prevalent Cases of Lewy Body Dementia by severity
  • Gender-specific Prevalence of Lewy Body Dementia
  • Diagnosed Cases of Episodic and Chronic Lewy Body Dementia

 

Download the report to understand which factors are driving Lewy Body Dementia epidemiology trends @ Lewy Body Dementia Epidemiology Forecast

 

Lewy Body Dementia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lewy Body Dementia market or expected to get launched during the study period. The analysis covers Lewy Body Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Lewy Body Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Lewy Body Dementia Therapies and Key Companies

  • E2027: Eisai
  • Neflamapimod: EIP Pharma
  • K0706: Sun Pharma
  • Galantamine: Neurological Research Center
  • LY3154207: Eli Lilly and Company
  • Nelotanserin: Axovant Sciences Ltd.
  • Neflamapimod: EIP Pharma Inc.
  • CT1812: Cognition Therapeutics
  • Irsenontrine: Eisai Inc.
  • Donepezil: Eisai Inc.
  • ATH-1017: Athira Pharma
  • Memantine: H. Lundbeck A/S
  • DatSCAN: GE Healthcare
  • CST-103: CuraSen Therapeutics
  • Armodafinil: Cephalon
  • RVT-101: Sio Gene Therapies
  • 18F-AV-133: Avid Radiopharmaceuticals

 

Discover more about therapies set to grab major Lewy Body Dementia market share @ Lewy Body Dementia Treatment Market

 

Lewy Body Dementia Market Strengths

  • Increasing research and development to understand the diversity of the disease might improve the diagnosis of LBD thereby resulting in a lucrative market opportunity
  • Current treatments are effective in relieving the symptoms and improving the quality of life of the patients

 

Lewy Body Dementia Market Opportunities

  • Several organizations are actively working to provide information and increase awareness of such disorders
  • There is only one approved treatment option for Lewy Body Dementia (LBD) which opens a platform of new therapies to boost the market of Lewy Body Dementia (LBD)
  • The pipeline for PMM is narrow as there is limited R&D activity

 

Scope of the Lewy Body Dementia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Lewy Body Dementia Companies: Eisai, EIP Pharma, Sun Pharma, Neurological Research Center, Eli Lilly and Company, Axovant Sciences Ltd., Cognition Therapeutics, Athira Pharma, H. Lundbeck A/S, GE Healthcare, CuraSen Therapeutics, Cephalon, Sio Gene Therapies, Avid Radiopharmaceuticals, and others
  • Key Lewy Body Dementia Therapies: E2027, Neflamapimod, K0706, Galantamine, LY3154207, Nelotanserin, Neflamapimod, CT1812, Irsenontrine, Donepezi, ATH-1017, Memantine, DatSCAN, CST-103, Armodafinil, RVT-101, 18F-AV-133, and others
  • Lewy Body Dementia Therapeutic Assessment: Lewy Body Dementia current marketed and Lewy Body Dementia emerging therapies
  • Lewy Body Dementia Market Dynamics: Lewy Body Dementia market drivers and Lewy Body Dementia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Lewy Body Dementia Unmet Needs, KOL’s views, Analyst’s views, Lewy Body Dementia Market Access and Reimbursement 

 

To know more about Lewy Body Dementia companies working in the treatment market, visit @ Lewy Body Dementia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Lewy Body Dementia Market Report Introduction

2. Executive Summary for Lewy Body Dementia

3. SWOT analysis of Lewy Body Dementia

4. Lewy Body Dementia Patient Share (%) Overview at a Glance

5. Lewy Body Dementia Market Overview at a Glance

6. Lewy Body Dementia Disease Background and Overview

7. Lewy Body Dementia Epidemiology and Patient Population

8. Country-Specific Patient Population of Lewy Body Dementia 

9. Lewy Body Dementia Current Treatment and Medical Practices

10. Lewy Body Dementia Unmet Needs

11. Lewy Body Dementia Emerging Therapies

12. Lewy Body Dementia Market Outlook

13. Country-Wise Lewy Body Dementia Market Analysis (2019–2032)

14. Lewy Body Dementia Market Access and Reimbursement of Therapies

15. Lewy Body Dementia Market Drivers

16. Lewy Body Dementia Market Barriers

17.  Lewy Body Dementia Appendix

18. Lewy Body Dementia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services